Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 29668H708 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Soleus Capital Master Fund, L.P.
13D/A
|
9.8% |
7/21/2025
Event 7/17/2025
|
||
| Soleus Capital Master Fund, L.P. | 9.8% | |||
| Soleus Capital, LLC | 9.8% | |||
| Soleus Capital Group, LLC | 9.8% | |||
| Soleus Capital Management, L.P. | 9.8% | |||
| Soleus GP, LLC | 9.8% | |||
| Guy Levy | 9.8% | |||
| BML Investment Partners, L.P. 13D | 9.5% |
4/24/2025
Event 4/24/2025
|
||
|
Soleus Capital, LLC
13G/A
|
5.1% |
2/11/2025
Event 12/31/2024
|
||
| Soleus Capital Special Opportunities Fund, L.P. | 0% | |||
| Soleus Capital Master Fund, L.P. | 5.1% | |||
| Soleus Capital, LLC | 5.1% | |||
| Soleus Capital Group, LLC | 5.1% | |||
| Soleus Capital Management, L.P. | 5.1% | |||
| Soleus GP LLC | 5.1% | |||
| Guy Levy | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (5) | ||||
|
Morgan Stanley
13G/A
|
4.0% |
10/7/2025
Event 9/30/2025
|
||
| Morgan Stanley | 4.0% | |||
| Morgan Stanley & Co. LLC | 0% | |||
|
RTW Investments, LP
13G/A
|
2.5% |
2/14/2025
Event 12/31/2024
|
||
| RTW Investments, LP | 2.5% | |||
| Roderick Wong, M.D. | 2.5% | |||
|
Biotechnology Value Fund L P
13D/A
|
0% |
10/14/2025
Event 10/9/2025
|
||
| Biotechnology Value Fund L P | 0% | |||
| BVF I GP LLC | 0% | |||
| Biotechnology Value Fund II LP | 0% | |||
| BVF II GP LLC | 0% | |||
| Biotechnology Value Trading Fund OS LP | 0% | |||
| BVF Partners OS Ltd. | 0% | |||
| BVF GP Holdings LLC | 0% | |||
| BVF Partners L P/IL | 0% | |||
| BVF Inc/IL | 0% | |||
| Lampert Mark N | 0% | |||
|
PFM Health Sciences, LP
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| PFM Health Sciences, LP | 0% | |||
| PFM Health Sciences GP, LLC | 0% | |||
| Partner Asset Management, LLC | 0% | |||
| Brian D. Grossman | 0% | |||
|
Tang Capital Management LLC
13G/A
|
0% |
11/14/2025
Event 9/30/2025
|
||
| Tang Capital Management, LLC | 0% | |||
| Kevin Tang | 0% | |||
| Tang Capital Partners, LP | 0% | |||
| Tang Capital Partners International, LP | 0% | |||
| Tang Capital Partners III, Inc | 0% | |||
| Tang Capital Partners IV, Inc | 0% | |||
| Concentra Biosciences, LLC | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 40 | 22.5 M | $4.30 M |
| 2025 Q2 | 44 | 31.0 M | $52.7 M |
| 2025 Q1 | 39 | 31.7 M | $50.1 M |
| 2024 Q4 | 48 | 32.8 M | $58.8 M |
| 2024 Q3 | 37 | 35.1 M | $213 M |
| 2024 Q2 | 37 | 39.4 M | $207 M |
| 2024 Q1 | 41 | 43.4 M | $368 M |
| 2023 Q4 | 38 | 39.0 M | $257 M |
| 2023 Q3 | 41 | 33.5 M | $103 M |
| 2023 Q2 | 46 | 33.3 M | $89.8 M |
| 2023 Q1 | 42 | 33.1 M | $98.3 M |
| 2022 Q4 | 51 | 33.4 M | $84.2 M |
| 2022 Q3 | 56 | 33.8 M | $62.2 M |
| 2022 Q2 | 61 | 37.8 M | $119 M |
| 2022 Q1 | 72 | 37.2 M | $230 M |
| 2021 Q4 | 62 | 37.3 M | $530 M |
| 2021 Q3 | 76 | 37.2 M | $297 M |
| 2021 Q2 | 82 | 34.2 M | $976 M |
| 2021 Q1 | 71 | 30.8 M | $896 M |
| 2020 Q4 | 41 | 23.1 M | $274 M |
| 2020 Q3 | 36 | 20.3 M | $139 M |
| 2020 Q2 | 21 | 14.1 M | $86.5 M |
| 2020 Q1 | 18 | 14.2 M | $56.6 M |
| 2019 Q4 | 22 | 13.9 M | $76.1 M |
| 2019 Q3 | 17 | 12.3 M | $41.0 M |
| 2019 Q2 | 10 | 5.48 M | $13.1 M |
| 2019 Q1 | 10 | 4.91 M | $16.8 M |
| 2018 Q4 | 9 | 3.83 M | $8.04 M |
| 2018 Q3 | 9 | 3.83 M | $11.5 M |
| 2018 Q2 | 8 | 2.75 M | $10.4 M |